Contineum Therapeutics, Inc. Assets, Fair Value Disclosure
Contineum Therapeutics, Inc. (CTNM) had Assets, Fair Value Disclosure of $234.40 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueDisclosure · last filed 2026-07-30
- 2026-06-30: Assets, Fair Value Disclosure $234.40M.
- 2026-03-31: Assets, Fair Value Disclosure $244.47M.
- 2025-12-31: Assets, Fair Value Disclosure $262.34M.
- 2024-12-31: Assets, Fair Value Disclosure $203.86M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $234.40M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $244.47M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $262.34M 10-Q · filed 2026-07-30 |
| 2024-12-31 | $203.86M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |